Use of a HIV derived accessory protein for the reactivation of latent HIV

Abstract

The present invention concerns the use of a protein comprising at least a HIV-derived accessory protein tat (trans-activator of transcription) or any derivative thereof for the reactivation of latent human immunodeficiency virus (HIV) from cells present in a HIV-infected patient.

1 .- 9 . (canceled) 
     
     
         10 . An isolated protein having the amino acid sequence of the group consisting of: SEQ ID. NO: 1, SEQ ID. NO: 2 and SEQ ID. NO: 3. 
     
     
         11 . An isolated protein of  claim 10 , wherein the protein has the amino acid sequence of SEQ ID. NO: 1. 
     
     
         12 . An isolated protein of  claim 10 , wherein the protein has the amino acid sequence of SEQ ID. NO: 2. 
     
     
         13 . An isolated protein of  claim 10 , wherein the protein has the amino acid sequence of SEQ ID. NO: 3. 
     
     
         14 . A pharmaceutical composition, comprising the protein of  claim 10 . 
     
     
         15 . A pharmaceutical composition of  claim 10 , wherein the protein has the amino acid sequence of SEQ ID. NO: 1. 
     
     
         16 . A pharmaceutical composition of  claim 10 , wherein the protein has the amino acid sequence of SEQ ID. NO: 2. 
     
     
         17 . A pharmaceutical composition of  claim 10 , wherein the protein has the amino acid sequence of SEQ ID. NO: 3. 
     
     
         18 . A method for treating a subject with human immunodeficiency virus (HIV) comprising the steps of:
 a) administering to said subject an effective amount of the composition of  claim 14 ; and   b) administering to said subject an effective amount of one or more anti-viral agent.   
     
     
         19 . A method of treating a subject of  claim 18 , wherein the subject is administered an effective amount of the composition of  claim 15 . 
     
     
         20 . A method of treating a subject of  claim 18 , wherein the subject is administered an effective amount of the composition of  claim 16 . 
     
     
         21 . A method of treating a subject of  claim 18 , wherein the subject is administered an effective amount of the composition of  claim 17 .